Since the advent of coronary artery bypass grafting (CABG), it has been one of the main ways to treat coronary heart disease. However, compared with percutaneous coronary intervention (PCI), it causes more trauma, complications and pain which discourage many patients. Recently, minimally invasive CABG has gradually become one of the main choices in some medical centers with the progress of technology and the development of surgical instruments. Compared with traditional CABG, minimally invasive CABG has the advantages of less trauma, less pain, faster recovery, lower perioperative mortality and less demand for blood transfusion. In this paper, we will mainly focus on the current stage and prospect of minimally invasive CABG.
Nowadays, the development of the medical instrument industry makes rapid changes in clinical practice. Hybridization of latest technology is playing an increasingly important role in the diagnosis and treatment of disease. Especially, the trend of the integration of three-channel hybrid technology in diagnosis and treatment of early lung cancer has become increasingly obvious. This paper will focus on the technical advance of the three-channel multi- mirror robot and its application in the diagnosis and treatment of early lung cancer.
Transcatheter intervention for congenital heart disease has been developed for 40 years in China, it has experienced the transition of learning to self-dependent innovation, and witnessed the intervention therapy system starting from scratch and gradually reaching the top level and gaining high achievements in the world scale. With the continuous development of interventional technology and devices, cutting-edge ideas and viewpoints are constantly discussed. This review summarized the development of intervention techniques and devices, hoping to provide some experience for the further development of transcatheter interventions for congenial heart disease.
Recently, an editorial in Cell Research illuminated the concept of the curative time window for lung adenocarcinoma. Within this window, patients could achieve 100.0% 5-year or 10-year post-operative recurrence-free survival. Adenocarcinoma in situ and minimally invasive adenocarcinoma in pathology, as well as pure ground-glass opacity in radiology could be regarded as the curative time window. However, not all the patients can catch this time window. A precise understanding of this concept helps elevate the curative rate for lung cancer patients and mitigate the risks of overdiagnosis and overtreatment. This article delves into the accurate comprehension of the surgical curative time window for lung adenocarcinoma, proposed a clinical strategy for early-stage lung adenocarcinoma, and introduced clinical procedures comprising of this time window. It offers fresh insights into the timing of surgical interventions for lung adenocarcinoma.